Skip to content
Search

Latest Stories

Royal College voting begins: A historic moment in the profession’s evolution

​RPS urges its members and fellows to vote in favour of Royal College for “a stronger, louder voice”

The Special Resolution Vote will remain open until 5 p.m. on Thursday, 24 March 2025.

Getty Images

Becoming a royal college will ensure pharmacy profession gains the recognition and authority it deserves, says RPS president Professor Claire Anderson.

Starting today (13), members and fellows of the Royal Pharmaceutical Society (RPS) will begin voting on the proposed changes to its Royal Charter, marking the beginning of a historic shift toward becoming the Royal College of Pharmacy.


The Special Resolution Vote will remain open until 5 p.m. on Thursday, 24 March 2025. A single vote will confirm both elements of the resolution - approval of the Charter amendments and the name change.

The RPS is strongly encouraging those eligible to support the creation of a royal college, highlighting key benefits such as:

  • a stronger, louder voice
  • commitment to collaboration
  • advancing and driving excellence in patient care
  • workforce transformation
  • a future-focused approach


“This is a historic moment in the profession’s evolution, enabling advanced practice, enhancing patient care and strengthening professional leadership,” said RPS president Professor Claire Anderson.

She emphasised that becoming a royal college will “ensure our profession gains the recognition and authority it deserves, uniting us under a shared banner of excellence, fostering collaboration and inclusivity across all sectors and specialties.”

“This is the moment to vote in support of the resolution and to champion the role of the profession in patient care and ensure pharmacy takes its rightful place amongst other healthcare professions,” she stated.

RPS chief executive Paul Bennett added that as the pharmacy profession continues to evolve, this transition represents “the next step in our journey.”

He explained: “A royal college will empower us to advocate more effectively, strengthen the profession’s leadership in healthcare, and provide the best support for our members.”

Paul also urged all eligible voters to “vote in support of the resolution made by Assembly and be part of shaping the future.”

Eligibility to vote extends to all pharmacists who are currently, or ever have been, registered with the pharmacy regulator and who are a Member (MRPharmS) or Fellow (FRPharmS) of RPS.

Voting eligibility is not dependent on the country a member lives in or whether they are retired or working.

The vote is being conducted by the independent scrutineer Mi-Voice, who will contact Members and Fellows directly about how to vote. Alternatively, votes can also be cast directly through the secure Mi-Voice website.

For the resolution to pass and move RPS toward becoming the Royal College of Pharmacy, at least two-thirds of the members who cast a vote must approve the changes.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less